Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Illumina is experiencing a return to growth, with a focus on its fourth quarter 2025 results [3] - The company emphasizes its differentiated ecosystem and workflow, which positions it well for continued growth, particularly in clinical markets [3] - Strategic positioning and disciplined execution are highlighted as key factors for profitable growth moving forward [3] Company Overview - Illumina is the market leader in next-generation sequencing, offering highly innovative products and maintaining the largest and most diverse installed base in the industry [4] - The company serves an installed base of over 20,000 instruments globally, spanning clinical, research, and applied markets [4] - This extensive scale allows Illumina to reach across the entire lifecycle from early discovery to routine clinical use [4]